Updated FAERS Analysis of Tirzepatide Safety: Emerging Adverse Event Signals | Research

The takeaway

Updated FAERS pharmacovigilance analysis of tirzepatide identifies emerging safety signals across gastrointestinal, hepatobiliary, and other organ systems as real-world use expands.

Emerging signals
Updated FAERS analysis reveals new adverse event signals beyond the expected GI effects as tirzepatide use expands globally

What the researchers found

Updated FAERS analysis identifies emerging adverse event signals for tirzepatide across GI, hepatobiliary, and other organ systems, characterizing its real-world safety profile.

Why it matters

Tirzepatide is one of the fastest-growing drugs ever. Early detection of safety signals protects millions of new users.

How the study worked

Pharmacovigilance analysis of updated FAERS data for tirzepatide, with proportional reporting and signal detection across organ systems.

What this study cannot tell us

FAERS reporting biases. Cannot determine causation or true incidence. Newer drugs may have amplified reporting due to media attention.

How to read the evidence

Pharmacovigilance database analysis. Important for signal detection but limited by FAERS reporting biases.

When this study was published

Published in 2025 with updated FAERS data.

The bigger picture

Post-marketing surveillance is essential for rapidly adopted drugs. This analysis tracks tirzepatide's safety evolution from controlled trials to mass market use.

Questions still open

Are the hepatobiliary signals clinically significant?
How does tirzepatide's safety compare to semaglutide in real-world data?
Should specific monitoring be recommended for new tirzepatide users?

Common questions

Are there new side effects being found with tirzepatide?

As more people use tirzepatide, new safety signals are emerging from adverse event reports. Beyond expected stomach issues, there are signals in liver/bile duct and other organ systems that need monitoring.

Should I be worried about these findings?

These are early signals from adverse event reporting, not proven side effects. Most patients tolerate tirzepatide well, but it is important to report any new symptoms to your doctor.

Read the original research

Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.

Drug, healthcare and patient safety, 18, 1-13

View on PubMed ↗Publisher’s paper ↗

Citation

Gu, Saisai. (2026). Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.. Drug, healthcare and patient safety, 18, 1-13. https://doi.org/10.2147/DHPS.S556918